Drugmaker Bharat Biotech on Friday said it has suspended the clinical studies of its vaccine with two Brazilian companies, which came after the Jair Bolsonaro-led Brazil ended its $324 million-contract for procuring 20 million Covaxin doses. Bharat Biotech said, "The company has terminated the said MoU with immediate effect. Notwithstanding such termination, Bharat Biotech will continue to work diligently with ANVISA, the Brazilian drug regulatory body to complete the regulatory approval process for Covaxin." "In the Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil. Amid the growing controversy, Bharat Biotech had last month denied any wrongdoing and said it had followed a “step-by-step" approach.

Source: dna July 24, 2021 12:22 UTC